BioTuesdays

Tag - Alethia Young

RAPT-Therapeutics
Markets

Cantor ups RAPT Therapeutics PT to $71 from $51

Cantor Fitzgerald raised its price target for RAPT Therapeutics (NASDAQ:RAPT) to $71 from $51, citing an increased probability of success for RPT193 in atopic dermatitis to 50% from 25% previously, and taking up peak...

June 14, 2021
Intercept-Pharma
Markets

Cantor cuts Intercept Pharma PT to $23 from $45

Cantor Fitzgerald reduced its price target for Intercept Pharmaceuticals (NASDAQ:ICPT) to $23 from $45 and maintained its “neutral” rating, citing first quarter financial results “which we think highlighted a lot of the...

May 7, 2021
Longbaord-Pharmaceuticals
Markets

Cantor starts Longboard Pharma at OW; PT $32

Cantor Fitzgerald launched coverage of Longboard Pharmaceuticals (NASDAQ:LBPH) with an “overweight” rating and $32 price target. The stock closed at $16.67 on April 5. Longboard was spun out of Arena Pharmaceuticals...

April 6, 2021
Eledon-Pharmaceuticals
Markets

Cantor starts Eledon Pharma at OW; PT $25

Cantor Fitzgerald launched coverage of Eledon Pharmaceuticals (NASDAQ:ELDN) with an “overweight” rating and $25 price target. The stock closed at $13.65 on March 22. Eledon is focused on developing AT-1501, which is an...

March 22, 2021
NexImmune-Logo
Markets

Cantor starts NexImmune at OW, PT $35

Cantor Fitzgerald launched coverage of NexImmune (NASDAQ:NEXI) with an “overweight” rating and price target of $35. The stock closed at $20.63 on March 8. NexImmune is developing a novel approach in cancer immunotherapy...

March 9, 2021
Akebia-Therapeutics-Logo
Markets

Cantor starts Akebia Therapeutics at OW; PT $8

Cantor Fitzgerald launched coverage of Akebia Therapeutics (NASDAQ:AKBA) with an “overweight” rating and $8 price target. The stock closed at $3.41 on March 5. The company’s lead asset, vadadustat, is an oral hypoxia...

March 8, 2021